New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
07:34 EDTMYLMylan launches Telmisartan Tablets
Mylan announced that it has launched Telmisartan Tablets USP, 20 mg, 40 mg and 80 mg, the generic version of Boehringer Ingelheim's Micardis Tablets. Mylan received final approval from the FDA for its Abbreviated New Drug Application, or ANDA, for this product, which is indicated for the treatment of hypertension, to lower blood pressure. Telmisartan Tablets USP, 20 mg, 40 mg and 80 mg, had U.S. sales of approximately $259.2M for the 12 months ending March 31 according to IMS Health.
News For MYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 13, 2015
16:23 EDTMYLMylan says offer to Perrigo delivers 'attractive' premium, immediate accretion
Subscribe for More Information
06:18 EDTMYLIrish Takeover Panel spurns Perrigo's request on Mylan bid, Reuters says
Subscribe for More Information
October 9, 2015
11:50 EDTMYLPerrigo releases full statement of Abbott CEO regarding Mylan stake
Subscribe for More Information
07:53 EDTMYLMylan to hold a conference call for Perrigo shareholders
Subscribe for More Information
October 7, 2015
09:35 EDTMYLMylan potential acquisition of Perrigo looks questionable says Bernstein
Subscribe for More Information
October 5, 2015
10:02 EDTMYLBofa/Merrill healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
September 30, 2015
14:58 EDTMYLMylan volatility at 52-week high
Mylan October weekly put option implied volatility is at 70, October is at 57, November is at 54; compared to its 52-week range of 26 to 58, suggesting large price movement.
11:06 EDTMYLStocks with call strike movement; FSLR MYL
First Solar (FSLR) January 50 call option implied volatility decreased 5% to 47, Mylan (MYL) January 47 call option implied volatility increased 4% to 48 according to IVolatility.
September 29, 2015
12:35 EDTMYLPerrigo shareholders pressure company to explore sale, Reuters says
Certain Perrigo (PRGO) shareholders have requested that company explore a sale, hoping for an alternative to Mylan's (MYL) approximately $25B hostile bid, Reuters reports, citing people familiar with the matter. The pressure represents a challenge to Perrigo's defense strategy, the report says. Some of the company's shareholders view Novartis (NVS), Sanofi (SNY), Procter & Gamble (PG), and Colgate-Palmolive (CL) as potential suitors, the report says. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use